{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:05Z","timestamp":1786997825333,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2025.110989","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:13:49Z","timestamp":1769080429000},"page":"110989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-0392","authenticated-orcid":false,"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"Guliyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakytzhan","family":"Ongarbayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunel","family":"Musaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramil","family":"Abdrakhmanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Chubenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Baklanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Zukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav","family":"Petkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilyara","family":"Kaidarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.110989_bib0001","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0002","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0003","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus Axitinib versus Sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0004","article-title":"Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101","volume":"8","author":"Tomita","year":"2023"},{"key":"10.1016\/j.urolonc.2025.110989_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.111","article-title":"A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)","author":"Hahn","year":"2025","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.urolonc.2025.110989_bib0006","article-title":"CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma. Eur Urol","volume":"S0302-2838","author":"Albiges","year":"2025"},{"key":"10.1016\/j.urolonc.2025.110989_bib0007","doi-asserted-by":"crossref","first-page":"oyae369","DOI":"10.1093\/oncolo\/oyae369","article-title":"Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study","volume":"30","author":"Zugman","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2025.110989_bib0008","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.urolonc.2025.110989_bib0009","article-title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial","volume":"S0923-7534","author":"Suarez","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0010","unstructured":"Press-release, Merck and Eisai announce WELIREG\u00ae (belzutifan) plus LENVIMA\u00ae (lenvatinib) met primary endpoint of progression-free survival (PFS) in certain previously treated patients with advanced renal cell carcinoma.https:\/\/www.merck.com\/news\/merck-and-eisai-announce-welireg-belzutifan-plus-lenvima-lenvatinib-met-primary-endpoint-of-progression-free-survival-pfs-in-certain-previously-treated-patients-with-advanced-renal-c\/ Accessed October 28, 2025."},{"key":"10.1016\/j.urolonc.2025.110989_bib0011","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2019.01.006","article-title":"Clonal deletion of tumor-specific T cells by interferon-\u03b3 confers therapeutic resistance to combination immune checkpoint blockade","volume":"50","author":"Pai","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.urolonc.2025.110989_bib0012","article-title":"A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models","volume":"23","author":"Tsimafeyeu","year":"2024","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0013","article-title":"Diversity of dominant peripheral T cell receptor clone and soluble immune checkpoint proteins associated with clinical outcomes following immune checkpoint inhibitor treatment in advanced cancers","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0014","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000505373","article-title":"Expression of receptor tyrosine kinases on peripheral blood mononuclear cells and tumor-infiltrating lymphocytes in patients with renal cell carcinoma and healthy donors","volume":"98","author":"Tsimafeyeu","year":"2020","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110989_bib0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41581-025-00983-w","article-title":"Haanen JBAG Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors","volume":"21","author":"Burgers","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.urolonc.2025.110989_bib0016","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2021.39.6_suppl.313","article-title":"Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"39","author":"Tannir","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2025.110989_bib0017","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.3390\/jcm14155271","article-title":"Decoding treatment failures in metastatic renal cell carcinoma: predictors across immunotherapy and targeted therapies from a retrospective real-world analysis","volume":"14","author":"Saftescu","year":"2025","journal-title":"J Clin Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:51:26Z","timestamp":1784548286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925005265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143925005265"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110989","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110989"}}